Amblyopia screening effectiveness at 3–4 years old: a cohort study. Issue 1 (4th January 2021)

• Record Type: Journal Article
• Authors: Guimaraes, Sandra; Soares, Andreia; Freitas, Cristina; Barros, Pedro; Leite, Ricardo Dourado; Costa, Patrício Soares; Silva, Eduardo D
• Is Part Of: BMJ open ophthalmology. Volume 6:Issue 1(2021)
• Publication Date: 2021-01-04
• Subjects: public health -- vision -- epidemiology; Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1136/bmjophth-2020-000599
• Languages: English
• ISSNs: 2397-3269

Abstract

Abstract : Objective: To study the effectiveness of amblyopia screening at ages 3–4. Methods and Analysis: From a population with no previous screening, a cohort of 2300 children with 3–4 years old attending school (91% of children this age attend school in Portugal), were submitted to a complete ophthalmological evaluation. Amblyopia was diagnosed, treated and followed. Amblyopia prevalence, treatment effectiveness, absolute risk reduction (ARR), number needed to screen (NNS) and relative risk reduction (RRR) were estimated. Results: Past/present history of amblyopia was higher than 3.1%–4.2%, depending on amblyopia definition normatives. Screening at age 3–4, had estimated ARR=2.09% (95% CI 1.50% to 2.68%) with a reduced risk of amblyopia in adulthood of 87% (RRR). NNS was 47.8 (95% CI 37.3 to 66.7). Treatment effectiveness of new diagnosis was 88% (83% if we include children already followed). 91% of new amblyopia diagnoses were refractive (of which 100% surpassed amblyopia Multi-Ethnic Pediatric Eye Disease Study criteria after treatment), while most strabismic amblyopias were already treated or undertreatment. Only 30% of children with refractive amblyopia risk factors that were not followed by an ophthalmologist, ended up having amblyopia at age 3–4. Eye patch was needed equally in new-diagnosis versus treated-earlier refractive amblyopia. Conclusions: Screening amblyopia in a whole-population setting at age 3–4 is highly effective. For each 48 children screened at age 3–4, one amblyopia is estimated to be prevented in the future (NNS). Screening earlier may lead to overdiagnosis and overtreatments: Treating all new diagnosis before age 3–4 would have a maximal difference in ARR of 0.3%, with the possible burden of as much as 70% children being unnecessary treated before age 3–4. Involving primary care, with policies for timely referral of suspicious/high-risk preverbal children, plus whole screening at age 3–4 seems a rational/effective way of controlling amblyopia.